



(51) International Patent Classification:

C07D 209/08 (2006.01) **C07C 251/32** (2006.01)
C07D 209/30 (2006.01)

(21) International Application Number:

PCT/GB2010/051100

(22) International Filing Date:

5 July 2010 (05.07.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/223,163 6 July 2009 (06.07.2009) US

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AINGE, Debra** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **BUTTERS, Michael** [GB/GB]; AstraZeneca, Avlon Works, Severn Road, Hallen Bristol BS10 7ZE (GB). **MERIFIELD, Eric** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **RAMAKRISHNAN, Ravi** [IN/IN]; AstraZeneca India Pvt Limited, Bellary Road, Hebbal, Bangalore 560 024 (IN). **RAYAPATI, Ravi Naidu** [IN/IN]; AstraZeneca India Pvt Limited, Bellary Road, Hebbal, Bangalore 560 024 (IN). **SHARMA,**

Parhalad Ray [IN/IN]; AstraZeneca India Pvt Limited, Bellary Road, Hebbal, Bangalore 560 024 (IN). **THOMSON, Colin** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO)) -3- [(4-CHLORO-PHENYL) THIO] -2-METHYL-1H-INDOLE-1-ACETIC ACID



(57) Abstract: The invention relates to compounds of formula (X), and salts thereof, and their use as intermediates in improved manufacturing processes for the synthesis of pharmaceutical compound of formula (I): X is =O, =N-OH or =N-OC(O)Me; Y is hydrogen, PhS- or *p*-chlorophenylsulfanyl; Z is hydrogen or -CH₂COOR¹ wherein R¹ is selected from hydrogen, optionally substituted hydrocarbyl and optionally substituted heterocycl.